J Clin Oncol: Efficacy and safety of CHOP regimen plus romidepsin in the treatment of relapsed/refractory peripheral T-cell lymphoma

Romidepsin is a histone deacetylase inhibitor that has been shown to be active as a single agent against relapsed or refractory peripheral T-cell lymphoma (PTCL)
.

Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) combination therapy is widely used as the first-line treatment of PTCL; however, the efficacy of this regimen is limited

Romidepsin is a histone deacetylase inhibitor lymphoma

This study is a randomized phase III study that compared the efficacy and safety of Ro-CHOP and CHOP regimens for previously untreated PTCL
.

All patients received 6 courses of CHOP (3 weeks/course); patients in the Ro-CHOP group received additional romidepsin (12 mg/m2, 3 weeks/course) on the 1st and 8th day of each course of treatment

Progression-free survival

Progression-free survival

From January 2013 to December 2017, a total of 421 patients (211 in the Ro-CHOP group and 210 in the CHOP group) were recruited
.

The median progression-free survival in the Ro-CHOP group and the CHOP group were 12.

The median progression-free survival of the Ro-CHOP group and the CHOP group were 12.

Overall survival

Overall survival

30% or more of patients in the Ro-CHOP group reported grade 3/4 side effects requiring emergency treatment, including thrombocytopenia (Ro-CHOP group vs CHOP group: 50% vs 10%), neutropenia (49% vs 33%), anemia (47% vs 17%) and leukopenia (32% vs 20%)

In summary, on the basis of the CHOP regimen, the addition of romidepsin did not improve the progression-free survival, remission rate and overall survival of patients with previously untreated peripheral T-cell lymphoma, and it also increased ≥3 grades The incidence of adverse events requiring urgent treatment

On the basis of the CHOP regimen, the addition of romidepsin did not improve the progression-free survival, remission rate, and overall survival of patients with previously untreated peripheral T-cell lymphoma, and it also increased the need for emergency ≥ grade 3 The incidence of treatment-related adverse events was based on the CHOP regimen.

Original source:

Emmanuel Bachy, et al.

Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA) in this message